Investigating Efficacy and Safety of Biphasic Insulin Aspart 50 Twice Daily Versus Biphasic Human Insulin 50 Twice Daily Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 161 participants.
Also called NCT01892020
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 161 participants
- Sponsor
- Registry
-
NCT01892020
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT01892020. Randomized; no masking; primary purpose treatment. Start 2013-06 (registry gives no type); primary completion 2014-05 (actual). Results posted on 2015-07-09.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Investigating Efficacy and Safety of Biphasic Insulin Aspart 50 Twice Daily Versus Biphasic Human Insulin 50 Twice Daily Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus
- Condition
- Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- biphasic insulin aspart 50
- Intervention (Drug)
- biphasic human insulin 50
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct01892020- Content hash
88b35ebe899f3198a30f6e5856038615a2336c8deb4b4fc91cac9b8f78de99c4